SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Wegovy Cut BMI by at Least 10% in Nearly 80% of Children in Trial

Novo Nordisk said nearly 80% of children aged 6 to under 12 with obesity achieved a BMI reduction of at least 10% with Wegovy, versus 0% with placebo in the phase 3 STEP Young trial. Results were published in The New England Journal of Medicine.

NVO

Related stories